Dermatology

Understanding the relationship between psoriasis and psoriatic arthritis can help.

Examining what immunotherapy can do for skin cancer treatment.

Valerie D. Callender, MD, FAAD, offers a look at the newest treatments available for acne and rosacea.

Immune checkpoint inhibitor therapy does not appear to increase complication rates in patients undergoing dermatologic procedures.

Several factors predict itch-specific quality of life in patients with chronic itch.

A recent article highlighted multiple forms of treatment for atopic dermatitis, detailing their benefits and adverse events.

More and more, clinicians are using oral minoxidil to treat patients with hair loss. Is it working?

Addressing the 2 inflammatory conditions requires careful consideration of the therapies to use.

Israeli researchers find more than fivefold risk of developing systemic sclerosis among people with vitiligo.

Experts discuss game-changing drugs and what’s in the pipeline.

BLA submission is based on phase 3 trial results evaluating the safety and efficacy of lebrikizumab.

Hidradenitis suppurativa is a chronic inflammatory skin condition that presents with painful, deep, and inflamed lesions found in flexural, apocrine gland-bearing sites.

Numerous adverse effects are associated with standard-dose isotretinoin.

State of Skin Sensitivity Report raises awareness of the causes of skin sensitivity and its effect on the mind.

Dry shampoo products were found to contain elevated levels of Benzene.

Understanding the main causes and staying current on recommendations and treatments will help reduce patient rates of the condition.

A recent review article lists six other JAK inhibitors that might be used as treatments for vitiligo in addition to ruxolitinib, the active ingredient in recently approved Opzelura.

A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.

Improvements in atopic dermatitis symptoms were seen in children taking dupilumab, with minimal adverse events.

Timber Pharmaceuticals’ CONTROL study evaluated the safety and efficacy of the topical isotretinoin.

New research examines how often immune-mediated inflammatory skin diseases occur in patients with inflammatory bowel disease.

Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium.

Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures versus traditional investigator-assessed studies.

Children with atopic dermatitis will soon have more options for treatment, as clinical trials show promising results.

Examining the results of a study examining the role of supplements and diets in managing psoriasis.